Scopus BioPharma Inc.
SCPS
$0.0003
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 935.90K | 1.07M | 1.09M | 981.30K | 2.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.93M | 2.68M | 1.84M | 1.90M | 3.32M |
| Operating Income | -2.93M | -2.68M | -1.84M | -1.90M | -3.32M |
| Income Before Tax | -2.93M | -2.68M | -1.84M | -1.90M | -3.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.93M | -2.68M | -1.84M | -1.90M | -3.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 312.30K | 229.80K | 105.10K | -- | -- |
| Net Income | -2.62M | -2.45M | -1.73M | -1.90M | -3.32M |
| EBIT | -2.93M | -2.68M | -1.84M | -1.90M | -3.32M |
| EBITDA | -2.93M | -2.68M | -1.84M | -1.90M | -3.32M |
| EPS Basic | -0.07 | -0.08 | -0.08 | -0.09 | -0.16 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.05 | -0.06 | -0.10 |
| EPS Diluted | -0.07 | -0.08 | -0.08 | -0.09 | -0.16 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.05 | -0.06 | -0.10 |
| Average Basic Shares Outstanding | 39.74M | 30.37M | 21.09M | 21.09M | 21.09M |
| Average Diluted Shares Outstanding | 39.74M | 30.37M | 21.09M | 21.09M | 21.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |